Background Idiopathic pulmonary fibrosis is a progressive, fatal disease with no known
efficacious therapy. Methods In a double-blind, multinational trial, we randomly assigned …

Background Idiopathic pulmonary fibrosis is a fatal disease for which no effective treatment
exists. We assessed whether treatment with interferon gamma-1b improved survival …

Background Patients with idiopathic pulmonary fibrosis have progressive scarring of the
lung and usually die within four to five years after symptoms develop. Treatment with oral …

Idiopathic pulmonary fibrosis (IPF)/usual interstitial pneumonia is a deadly disease with no
effective treatment. The purpose of this randomised prospective multicentric study was to …

Background: Prospective data defining the clinical course in idiopathic pulmonary fibrosis
(IPF) are sparse. Objective: To analyze the clinical course of patients with mild to moderate …

Background Idiopathic pulmonary fibrosis (IPF) is a devastating disease, yet validated,
reliable criteria for evaluating patient response to therapies in clinical trials are lacking …

In a recent study of IFN-γ 1b in 330 patients with idiopathic pulmonary fibrosis (IPF),
progression-free survival was unchanged; however, a trend toward lower mortality was seen …

Definitive evidence of clinical efficacy in a Phase 3 trial is best shown by a beneficial impact
on a clinically meaningful endpoint—that is, an endpoint that directly measures how a …

Rationale: FVC has emerged as a standard primary endpoint in clinical trials evaluating
novel therapies for patients with idiopathic pulmonary fibrosis (IPF). However, it has recently …

The clinical course of idiopathic pulmonary fibrosis (IPF) is variable; however, the long-term
survival in IPF is poor. Prednisone has been the mainstay of therapy since its release for …